False halo sign secondary to calcification of temporal artery

2021 ◽  
Vol 157 (7) ◽  
pp. 352-353
Author(s):  
Luis Marhuenda-Bermejo ◽  
Óscar Ayo-Martín ◽  
Jorge García-García
Keyword(s):  
2021 ◽  
pp. 10.1212/CPJ.0000000000001083
Author(s):  
Valentina Poretto ◽  
Silvio Piffer ◽  
Valeria Bignamini ◽  
Enzo Tranquillini ◽  
Davide Donner ◽  
...  

A 74-year-old woman presented with acute worsening of six-months long history of vertigo and postural instability, with MRI evidence of cerebellar and brainstem acute infarcts. Extensive neurovascular assessment revealed a severe vascular damage with multiple stenoses and occlusions along vertebrobasilar axis (figure 1). Duplex ultrasonography showed hypoechoic halo sign along facial artery, while PET-CT highlighted increased [18F]-FDG uptake along vertebral and other larger arteries, thus allowing a diagnosis of giant cell arteritis (figure 2).1,2 Despite prompt treatment with high-dose steroids and tocilizumab, which probably made uninformative a subsequent temporal artery biopsy (figure 2), patient died of reported disability after strokes.


Rheumatology ◽  
2020 ◽  
Vol 59 (9) ◽  
pp. 2443-2447 ◽  
Author(s):  
Elisa Fernández-Fernández ◽  
Irene Monjo-Henry ◽  
Gema Bonilla ◽  
Chamaida Plasencia ◽  
María-Eugenia Miranda-Carús ◽  
...  

Abstract Objectives To describe the frequency and causes for the presence of a halo sign on the ultrasound of patients without a diagnosis of GCA. Methods In total, 305 patients with temporal artery colour Doppler ultrasound showing the presence of halo sign (intima-media thickness ≥0.34 mm for temporal arteries [TAs] and ≥1 mm for axillary arteries) were included, and their medical records were reviewed. The clinical diagnosis based on the evolution of the patient over at least one year was established as the definitive diagnosis. Results Fourteen of the 305 (4.6%) patients included showed presence of the halo sign without final diagnosis of GCA: 12 patients in the TAs (86%), and two patients with isolated AAs involvement (14%). Their diagnoses were PMR (n = 4, 29%); atherosclerosis (n = 3, 21%); and non-Hodgkin lymphoma type T, osteomyelitis of the skull base, primary amyloidosis associated with multiple myeloma, granulomatosis with polyangiitis, neurosyphilis, urinary sepsis and narrow-angle glaucoma (n = 1 each, 7%). Conclusion The percentage of halo signs on the ultrasound of patients without GCA is low, but it does exist. There are conditions that may also show the halo sign (true positive halo sign), and we must know these and always correlate the ultrasound findings with the patient’s clinic records.


2006 ◽  
Vol 79 (947) ◽  
pp. e184-e186 ◽  
Author(s):  
M W T Arnander ◽  
N G Anderson ◽  
F Schönauer

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1562.3-1562
Author(s):  
A. Sidhu ◽  
A. Bharadwaj ◽  
A. Nandagudi

Background:Giant cell arteritis (GCA) is an emergency. The initial treatment with high dose glucocorticoids (GC) is often started on clinical suspicion without waiting for Temporal artery biopsy (TAB) results, which can take days to be available. TAUS is a simple, non-invasive test which is readily available. However, like any other ultrasound, it is also operator dependent. A positive halo sign is the most specific abnormality seen on TAUS in GCA patients. The percentage of false positive TAUS in GCA diagnosis is low (1), but it can result in over diagnosis and unnecessary exposure to high dose GC in elderly population.Objectives:We looked at the reliability of TAUS in ruling out GCA after it was introduced within our rheumatology department one year ago.Methods:We adopted the quality improvement methodology for assessment. Retrospective data of suspected GCA patients was collected over the last two years. TAUS was introduced regularly to the investigative plan after eleven months. Two Rheumatology consultants were trained in TAUS. Results were compared before and after the introduction of ultrasound as a diagnostic tool. In collecting the data, our main focus for documentation was based on clinical symptoms, TAUS and TAB results. We aimed to increase the awareness of appropriate GCA referrals among the primary and secondary care with the support of teaching sessions.Results:From January 2018 to November 2019, 101 patients were referred to rheumatology with suspected GCA. Median age of our cohort was 72 years with male to female ratio of 1:3. 35 patients were referred in the first 11 months out of which, 10 (28.6%) were diagnosed with GCA. TAUS and TAB was done in 20% and 49% of patients respectively. 66 patients were referred in the next 12 months after TAUS was introduced. Out of 66, 14 patients (21.2%) were diagnosed as GCA. TAUS and TAB were done in 82% and 38% of the patients respectively. As listed in table 1, only 1 patient was found to have positive TAB after a negative TAUS (false negative). All of patients with positive TAUS were treated as GCA on the basis of clinical grounds, irrespective of TAB results. Despite the regular use of TAUS as a diagnostic tool in the second phase, there is a higher percentage of patients (78.8%) in which GCA was ruled out.TAUS introductionBefore regular TAUS(Jan 2018 – Nov 2018)After regular TAUS(Dec 2018 – Nov 2019)Patients referred3566GCA10 (28.6%)14 (21.2%)Not GCA25 (71.4%)52 (78.8%)TAUS done in20%82%TAB done in49%38%TAUS -ve and TAB +ve01TAUS +ve and TAB -ve/not done28Conclusion:After the routine introduction of TAUS, the percentage of patients diagnosed with GCA has declined and clinicians have been able to exclude suspected GCA diagnosis in a larger proportion of patients referred. This is noteworthy as our Rheumatologists are still in the learning phases of determining the significance of utility of TAUS. There is only a small decline in TAB frequency, which is expected to go down further in the coming years. We also noticed that the number of patients referred has almost doubled. This might be due to better education and awareness at the primary and secondary care level which was done as part of the project.References:[1]Fernández E, Monjo I, Bonilla G, et alOP0210 FALSE POSITIVES OF ULTRASOUND IN GIANT CELL ARTERITIS. SOME DISEASES CAN ALSO HAVE HALO SIGNAnnals of the Rheumatic Diseases2019;78:181Disclosure of Interests:None declared


2010 ◽  
Vol 37 (11) ◽  
pp. 2326-2330 ◽  
Author(s):  
CARLA MALDINI ◽  
CAROLINE DÉPINAY-DHELLEMMES ◽  
THI T.S. TRA ◽  
MICHEL CHAUVEAU ◽  
YANNICK ALLANORE ◽  
...  

Objective.Use of TA-US for diagnostic investigation of giant cell arteritis (GCA) has been proposed but remains a matter of debate because of the heterogeneous findings. We retrospectively evaluated operating characteristics of temporal artery ultrasonography (TA-US) in a single teaching hospital.Methods.All subjects with suspected GCA had been seen between 2002 and 2008 and had undergone TA-US with continuous-wave Doppler (until 2004) or color duplex ultrasonography (after 2004), followed within 30 days by a temporal artery biopsy (TAB). TA-US findings were compared with TAB-proven GCA and clinically diagnosed GCA. Results are expressed as sensitivities, specificities, and positive (LR+) and negative likelihood ratios (LR−) of stenoses, occlusions, and the halo sign; for the latter, only color duplex TA-US was considered.Results.Seventy-seven patients fulfilled the selection criteria; 13 had TAB-proven and 19 had clinically defined GCA. Stenoses/occlusions were seen on 45.5% of TA-US and the halo sign was seen only once (3.2%) in 31 duplex TA-US. Respective sensitivities, specificities, LR+, and LR− for GCA diagnosis (using TAB-proven/clinically defined GCA as reference standards) were 69%/53%, 59%/57%, 1.7/1.2, and 0.5/0.8 for stenoses and/or occlusions, and 17%/10%, 100%/100%, infinite/infinite, and 0.8/0.9 for the halo sign.Conclusion.The halo sign showed 100% specificity for GCA but only 10%–17% sensitivity. Stenoses/occlusions were of low diagnostic value. These observations suggest that TA-US is neither an effective substitute for TAB nor a reliable screening test to decide which patients can be safely spared TAB.


2020 ◽  
pp. 1-8
Author(s):  
Ryosuke Tashiro ◽  
Miki Fujimura ◽  
Masahito Katsuki ◽  
Taketo Nishizawa ◽  
Yasutake Tomata ◽  
...  

OBJECTIVESuperficial temporal artery–middle cerebral artery (STA-MCA) anastomosis is the standard surgical management for moyamoya disease (MMD), whereas cerebral hyperperfusion (CHP) is one of the potential complications of this procedure that can result in delayed intracerebral hemorrhage and/or neurological deterioration. Recent advances in perioperative management in the early postoperative period have significantly reduced the risk of CHP syndrome, but delayed intracerebral hemorrhage and prolonged/delayed CHP are still major clinical issues. The clinical implication of RNF213 gene polymorphism c.14576G>A (rs112735431), a susceptibility variant for MMD, includes early disease onset and a more severe form of MMD, but its significance in perioperative pathology is unknown. Thus, the authors investigated the role of RNF213 polymorphism in perioperative hemodynamics after STA-MCA anastomosis for MMD.METHODSAmong 96 consecutive adult patients with MMD comprising 105 hemispheres who underwent serial quantitative cerebral blood flow (CBF) analysis by N-isopropyl-p-[123I]iodoamphetamine SPECT after STA-MCA anastomosis, 66 patients consented to genetic analysis of RNF213. Patients were routinely maintained under strict blood pressure control during and after surgery. The local CBF values were quantified at the vascular territory supplied by the bypass on postoperative days (PODs) 1 and 7. The authors defined the radiological CHP phenomenon as a local CBF increase of more than 150% compared with the preoperative values, and then they investigated the correlation between RNF213 polymorphism and the development of CHP.RESULTSCHP at POD 1 was observed in 23 hemispheres (23/73 hemispheres [31.5%]), and its incidence was not statistically different between groups (15/41 [36.6%] in RNF213-mutant group vs 8/32 [25.0%] in RNF213–wild type (WT) group; p = 0.321). CHP on POD 7, which is a relatively late period of the CHP phenomenon in MMD, was evident in 9 patients (9/73 hemispheres [12.3%]) after STA-MCA anastomosis. This prolonged/delayed CHP was exclusively observed in the RNF213-mutant group (9/41 [22.0%] in the RNF213-mutant group vs 0/32 [0.0%] in the RNF213-WT group; p = 0.004). Multivariate analysis revealed that RNF213 polymorphism was significantly associated with CBF increase on POD 7 (OR 5.47, 95% CI 1.06–28.35; p = 0.043).CONCLUSIONSProlonged/delayed CHP after revascularization surgery was exclusively found in the RNF213-mutant group. Although the exact mechanism underlying the contribution of RNF213 polymorphism to the prolonged/delayed CBF increase in patients with MMD is unclear, the current study suggests that genetic analysis of RNF213 is useful for predicting the perioperative pathology of patients with MMD.


Sign in / Sign up

Export Citation Format

Share Document